publication date: May. 10, 2019

Real World Evidence FDA issues draft guidance on using real world data in drugs, biologics

By Matthew Bin Han Ong

FDA has issued a draft guidance that describes the types of real world data and real world evidence that the agency would accept as part of regulatory submissions for drugs and biologics.

The draft guidance, published May 8, is intended to get input on FDA’s proposal to “encourage sponsors and applicants who are using RWD to generate RWE as part of a regulatory submission to identify in the cover letter that the submission contains RWE in a simple, uniform format,” agency officials said in a statement.

The comment period is open through the first week of July.

When implemented, FDA anticipates that this approach will allow the agency to identify and track RWE submissions, monitor outcomes and ensure appropriate review expertise.

“This is a harbinger of many more things to come at FDA,” Amy Abernethy, FDA deputy principal commissioner, said to The Cancer Letter. Abernethy, who joined the agency in February, is also acting chief information officer (The Cancer Letter, Dec. 17, 2018).

According to the draft guidance, submissions for drugs and biologics may include RWE used to support study objectives. For instance:

Continue reading FDA issues draft guidance on using real world data in drugs, biologics

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.